In a groundbreaking study, researchers from the University of New South Wales and the University of California-Los Angeles utilized a target trial emulation framework to analyze patient outcomes for serious bacterial infections. Focusing on cases from October 2015 to October 2022, the study compared the effectiveness of laLGPs (dalbavancin and oritavancin) versus standard-of-care antibiotics in hospitalized individuals. While laLGPs are currently approved for skin infections, they demonstrated potential as a viable option for outpatient parenteral antibiotic therapy (OPAT) in more severe infections, particularly among people who use drugs (PWUD). This innovative approach could revolutionize treatment strategies for bacterial infections and improve outcomes for a diverse range of patients.
Read more about this — here
